Novelskin, a brand of aesthetic medicine and cosmetic care, has announced the acquisition of the biomedical research laboratory Nunii. This first acquisition for Novelskin is part of a dynamic to offer ever more targeted dermo-aesthetic treatments to professionals, but also to the general public.
Novelskin has built its expertise around skin problems such as pigmentation spots, acne or the appearance of wrinkles and fine lines. The brand wishes to go further in its R&D. This is why it chose Nunii and hopes to continue its fundamental research on the mechanisms of melanogenesis.
“With the acquisition of Nunii, Novelskin now becomes a major player in the treatment of pigmentation and acne with its own R&D laboratory. Novelskin’s ambition is to develop the brand on the French market and internationally. New products will be marketed as early as 2022,” said Karine Popis-Claude, founder of Novelskin.
